Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 37% Improvement Relative Risk Case, close contact 52% Becetti et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 700 patients in Qatar (April - July 2020) Fewer cases with HCQ (not stat. sig., p=0.17) Becetti et al., Qatar Medical J., doi:10.5339/qmj.2022.37 Favors HCQ Favors control
Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar
Becetti et al., Qatar Medical Journal, doi:10.5339/qmj.2022.37
Becetti et al., Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases.., Qatar Medical Journal, doi:10.5339/qmj.2022.37
Aug 2022   Source   PDF  
  All Studies   Meta
Retrospective 700 patients with autoimmune rheumatic disease in Qatar, showing lower risk of COVID-19 with HCQ use, without statistical significance. For patients having close contact with COVID-19 cases, there was a statistically significant association with HCQ use and lower risk of COVID-19 in unadjusted results.
risk of case, 36.8% lower, RR 0.63, p = 0.17, treatment 26 of 314 (8.3%), control 49 of 386 (12.7%), NNT 23, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of case, 52.0% lower, RR 0.48, p < 0.001, treatment 16 of 46 (34.8%), control 29 of 40 (72.5%), NNT 2.7, patients with close contact to cases, close contact.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Becetti et al., 5 Aug 2022, retrospective, Qatar, peer-reviewed, mean age 43.2, 12 authors, study period 1 April, 2020 - 31 July, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: RESEARCH PAPER Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar Karima Becetti1*, Eman Satti1*, Betsy Varughese2, Yousef Al Rimawi1, Rawan Sheikh Saleh1, Nawal Hadwan1, Miral H Gharib1, Mohamed Awni Al Kahlout1, Essa Abuhelaiqa3, Hadil Afif Ashour1, Rajvir Singh4, Samar Al Emadi1 Address for Correspondence: Karima Becetti, Eman Satti1* 1 Division of Rheumatology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar 2 Gastroenterology & Hepatology, Medicine, Hamad Medical Corporation, Doha, Qatar 3 Division of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar 4 Cardiology Research Center, Heart Hospital, Hamad Medical Corporation, Doha, Qatar *These authors contributed equally to this work Email: Submitted: 13 January 2022 Accepted: 25 May 2022 © 2022 Becetti, Satti, Varughese, Al Rimawi, Saleh, Hadwan, Gharib, Al Kahlout, Abuhelaiqa, Ashour, Singh, Al Emadi, licensee HBKU Press. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. Cite this article as: Becetti K, Satti E, Varughese B, Al Rimawi Y, Saleh RS, Hadwan N, Gharib MH, Al Kahlout MA, Abuhelaiqa E, Ashour HA, Singh R, Al Emadi S. Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar, Qatar Medical Journal 2022(3):37 ABSTRACT Background: Autoimmune rheumatic diseases (ARDs) are characterized by immune dysfunction and associated with an increased risk of infections, which were of significant concern during the coronavirus disease 2019 (COVID-19) pandemic. Variable rates of COVID-19 incidence have been reported in patients with ARDs; however, the true effect of this infection on this patient population is still unclear. We, therefore, aimed to evaluate the COVID-19 prevalence among a multiethnic cohort of patients with ARDs in Qatar. Material and Methods: We used telephonic surveys to collect demographic and clinical information of patients with ARD in Qatar between April 1 and July 31, 2020, including any close contact with a COVID19 case at home or work and polymerase chain reaction (PCR)-confirmed COVID-19 diagnosis. An electronic medical records review was conducted to verify pertinent data collected through the surveys. Prevalence with 95% confidence interval (CI), Student’s t-tests, and chi-square/Fisher’s exact tests were used for univariate analyses, whereas multivariate logistic regression was used to identify factors associated with COVID-19. Results: The study included 700 patients with ARD (mean age, 43.2 ^ 12.3 years), and 73% were female. Until July 2020, 75 (11%, 95% CI 9% –13%) patients had COVID-19. Factors associated with COVID-19 included being a man (adjusted odds ratio [aOR] 2.56, 95% CI 1.35–4.88, p ¼ 0.01) and having close contact with a COVID-19 case (aOR 27.89, 95% CI 14.85–52.38, p ¼ 0.01). Disease severity and rheumatic medications had no significant QATAR MEDICAL JOURNAL 1 VOL. 2022 / ART. 37 Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases association with the odds of contracting COVID-19. In the 86 patients with ARD having close contact,..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop